Sunny Pharmtech

Sunny Pharmtech Net Margin

The Net Profit Margin of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -37.32 %. In the previous year, Net Profit Margin was -14.77 % — a change of 152.75% (lower).

Net Margin

-37.32 %

YoY

152.75%

Last updated:

Net Profit Margin of Sunny Pharmtech is 2024 -37.32 % . Net Profit Margin of Sunny Pharmtech was 2023 -14.77 % . It decreases by 152.75% lower compared to the previous year.

Sunny Pharmtech's net margin stands at -37.3%, down from -24.2% several years earlier.

The Sunny Pharmtech Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-209.80 TWD
Jan 1, 2019
-96.51 TWD
Jan 1, 2020
-24.23 TWD
Jan 1, 2021
-72.53 TWD
Jan 1, 2022
-47.34 TWD
Jan 1, 2023
-14.77 TWD
Jan 1, 2024
-37.32 TWD
The Sunny Pharmtech Net Margin history
YEARNet MarginYoY
-37.32 %+152.75%
-14.77 %-68.81%
-47.34 %-34.72%
-72.53 %+199.31%
-24.23 %-74.89%
-96.51 %-54.00%
-209.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Net Profit Margin of Sunny Pharmtech is -37.32 % in 2024.

Net Profit Margin of Sunny Pharmtech changed from -14.77 % to -37.32 %, representing a 152.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech